ArticleJournal of the American Heart Association2025
Age and Health Status Benefits Following Initiation of Atrial Fibrillation-Specific Treatments.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) is managed with various strategies, including rate and rhythm control, to improve patients' health status. Although its incidence increases with age, how age affects health status improvements following AF treatment remains unknown.
methodsUsing data from a multicenter registry for outpatients with newly recognized AF, baseline and 1-year health status was assessed with the Atrial Fibrillation Effect on Quality-of-life quesTionnaire (AFEQT). The associations between age and 1-year changes in AFEQT-overall summary and subdomain scores with rate or rhythm control strategies were estimated using generalized additive models. To address nonlinear relationships, we developed multivariable linear regression models with age range categories (<65, 65-75, and ≥75 years).
resultsAmong 2786 patients (31.7% women); 946 were <65, 1019 were ≥65 to 75, and 821 were ≥75 years, with rate control pursued in 23.4%, 42.0%, and 66.4%, respectively, and their mean 1-year improvements in the AFEQT overall summary were 11.1 (SD: 16.6), 8.0 (17.0), and 4.7 (18.2), respectively. After multivariable adjustment, older age was independently associated with less AFEQT overall summary improvement, regardless of treatment strategy. Patients aged ≥75 years had a smaller AFEQT overall summary improvements than those aged <65 years (difference between groups -3.86 points [-5.29 to -2.42]), primarily driven by smaller improvements in AFEQT daily activities scores with similar improvements in the AFEQT symptoms or treatment concern domains.
conclusionsAlthough older adults with AF exhibited smaller gains in functional limitation following disease-specific treatment, they experienced measurable improvements in overall health status regardless of treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.